In the first study, 19% of the patients adding the approved dose of Rapamune had failed treatment after six months (53 out of 284), compared with 32% of those adding azathioprine (52 out of 161).
Võrreldes 32% - ga (52 patsienti 161- st) patsientidest, kellele manustati lisaks asatiopriini, ebaõnnestus esimeses uuringus ravi kuue kuu möödudes 19% - l patsientidest (53 patsiendil 284- st), kellele manustati lisaravimina Rapamune heakskiidetud annus.